[Angiogenesis inhibitors for treatment of angiodysplasia-related gastrointestinal bleeding].
Bauditz
Jürgen
J
IV. Medizinische Klinik und Poliklinik, Universitätsklinikum Charité, Berlin. Juergen.Bauditz@charite.de
D016888:Angiodysplasia / Q000150:complications* / Q000235:genetics; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002196:Capillaries / Q000473:pathology; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D041981:Gastrointestinal Tract / Q000098:blood supply*; D006801:Humans; D007413:Intestinal Mucosa / Q000098:blood supply; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications / Q000235:genetics; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D013792:Thalidomide